All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

How does pre-transplant MRD affect outcome in AML?

During the EHA2021 Virtual Congress, the AML Hub spoke with Arnon Nagler, Tel Aviv University, Tel Aviv, IL. We asked, How does pre-transplant measurable residual disease (MRD) affect outcome in AML?

How does pre-transplant MRD affect outcome in AML?

In this video, Nagler discusses how pre-transplant MRD, the most important predictive factor, affects the outcome of transplantation in AML. Patients who are MRD-negative pre-transplant have a lower relapse rate, and better leukemia-free and overall survival; however, MRD does not appear to affect transplant-related mortality. Nagler goes on to describe the results of a study investigating whether MRD dictates transplant results in patients that received post-transplant cyclosporine as graft-versus-host disease prophylaxis.

 

Share:
More about...